ProPhase Labs (NASDAQ:PRPH) Now Covered by StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of ProPhase Labs (NASDAQ:PRPH) in a research note issued on Thursday. The firm set a “sell” rating on the stock.

ProPhase Labs Stock Down 4.1 %

PRPH traded down $0.02 on Thursday, hitting $0.49. The company had a trading volume of 338,862 shares, compared to its average volume of 438,242. ProPhase Labs has a 52-week low of $0.46 and a 52-week high of $7.48. The stock has a fifty day simple moving average of $0.69 and a 200-day simple moving average of $1.89. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.47 and a quick ratio of 1.33. The firm has a market capitalization of $11.70 million, a P/E ratio of -0.39 and a beta of -0.30.

Institutional Trading of ProPhase Labs

Hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC raised its stake in ProPhase Labs by 9.2% during the third quarter. Geode Capital Management LLC now owns 160,735 shares of the company’s stock valued at $389,000 after buying an additional 13,590 shares during the last quarter. HighTower Advisors LLC grew its stake in shares of ProPhase Labs by 18.3% in the third quarter. HighTower Advisors LLC now owns 179,045 shares of the company’s stock worth $434,000 after acquiring an additional 27,673 shares during the last quarter. Finally, Sheets Smith Wealth Management bought a new position in shares of ProPhase Labs during the fourth quarter valued at $158,000. 9.45% of the stock is owned by hedge funds and other institutional investors.

About ProPhase Labs

ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.